日本皮膚科学会雑誌
Online ISSN : 1346-8146
Print ISSN : 0021-499X
乾癬におけるTNFα阻害薬の使用指針および安全対策マニュアル
大槻 マミ太郎照井 正小澤 明森田 明理佐野 栄紀髙橋 英俊小宮根 真弓江藤 隆史鳥居 秀嗣朝比奈 昭彦根本 治中川 秀己
著者情報
ジャーナル 認証あり

120 巻 (2010) 2 号 p. 163-171

詳細
PDFをダウンロード (899K) 発行機関連絡先
抄録

Anti-TNFα (tumor necrosis factor-α) agents, adalimumab and infliximab, are the first biologics approved for the treatment of psoriasis in Japan. Although these agents are expected to have remarkable effects on psoriasis and/or psoriatic arthritis, and to improve QOL (quality of life) of patients with psoriasis, there is growing concern regarding the potential serious adverse reactions such as infections including tuberculosis as well as bacterial and Pneumocystis pneumonia. The guideline and safety manual have been developed to ensure that anti-TNFα agents are properly used by board-certified dermatologists experienced in practice of psoriasis. Requirements for physicians and medical institutions, eligible patients for treatment with anti-TNFα agents, dosage and administration of each anti-TNFα agents, general considerations for administration, contraindications, safety precautions for high-risk patients for adverse reactions, and recommendable combination therapies with anti-TNFα agents are referred.

著者関連情報
© 2010 日本皮膚科学会
次の記事

閲覧履歴
feedback
Top